Cash and dilution
It reported cash of $11K as of Sep 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
At its recent quarterly burn rate that cash lasts about 0.1 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
Its share count rose 11.0% over the past year. (Company health, computed by us from SEC filings and XBRL, Nov 9, 2026)
The stock
The Nasdaq screener puts its market value at $24.5M. (Nasdaq stock screener, Nov 13, 2026)
ABVC BioPharma Inc. puts a 424B4 prospectus supplement on file
On Nov 13, 2026, ABVC BioPharma Inc. (ABVC) filed a 424B4: a final prospectus with the offering's price. (SEC EDGAR, 424B4, Nov 13, 2026)
ABVC BioPharma Inc. files a 424B4 prospectus supplement
ABVC BioPharma Inc. (ABVC) filed a 424B4 on Nov 13, 2026, a final prospectus with the offering's price. (SEC EDGAR, 424B4, Nov 13, 2026)
ABVC BioPharma Inc. puts a 424B4 prospectus supplement on file
On Nov 13, 2026, ABVC BioPharma Inc. (ABVC) filed a 424B4: a final prospectus with the offering's price. (SEC EDGAR, 424B4, Nov 13, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/ABVC)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.